Shubhanshu Shukla set to script history as India's second astronaut in space
New Delhi, India's Shubhanshu Shukla is set for his maiden space flight as part of Axiom Space's fourth commercial mission to the International Space Station, which is scheduled for lift-off onboard SpaceX's Falcon-9 rocket from the Kennedy Space Centre in Florida on June 8.
The launch of the Dragon spacecraft will take place not earlier than 6:41 pm IST from NASA's spaceport in Florida, making Shukla only the second Indian to travel to space four decades after Rakesh Sharma's iconic spaceflight onboard Russia's Soyuz spacecraft in 1984.
Besides Shukla, the mission pilot for the Axiom-4 mission, the other crew include Slawosz Uznanski-Wisniewski from Poland and Tibor Kapu from Hungary, marking both European nation's first travel to the International Space Station in history and the second government-sponsored human spaceflight mission in over 40 years.
Veteran US astronaut Peggy Whitson will be the commander of the Axiom-4 mission.
"I am really, really excited to go into microgravity and experience spaceflight on my own," Shukla, who goes by the nickname 'Shuks', said at a press conference in January.
Once docked, the astronauts plan to spend up to 14 days aboard the orbiting laboratory, conducting science, outreach, and commercial activities.
The Ax-4 astronauts will perform around 60 scientific studies and activities representing 31 countries during their 14-day stay at the ISS.
Shukla is set to conduct exclusive food and nutrition-related experiments developed under a collaboration between the Indian Space Research Organisation and the Department of Biotechnology , with support from NASA.
The experiments aim to pioneer space nutrition and self-sustaining life support systems vital for future long-duration space travel.
ISRO has lined up a set of seven experiments for Shukla, who will also participate in five joint studies planned by NASA for its human research program.
It has drawn up plans to focus on India-centric food for carrying out experiments on the ISS, including sprouting methi and moong in microgravity conditions.
Shukla will also expose the seeds to the macrobiotic conditions and bring them back to earth where they will be cultivated in plants not just once but over generations.
In January, Shukla said he also planned to capture his experiences on board the ISS through pictures and videos which can be shared with all the "'Bharatvaasis' back home."
"I want them to share this thrilling experience through my eyes, for I truly believe that, even as an individual travelling to space, this is the journey of 1.4 billion people," he said.
Shukla said he planned to take certain items from different parts of the country with him to the ISS during the 14-day mission and even expressed hope to serve Indian food to astronauts in the orbital laboratory.
He said the experience on the Axiom Mission 4 would be very well utilised on the Gaganyaan mission which is planned for 2027. ISRO is spending ₹550 crore on the Axiom-4 mission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Gelatin from goat skin offers non-bovine, non-pork alternative to food, pharma sectors
Hyderabad: A superior gelatin extracted from the skin of Black Bengal goats with likely use in pharma and food sectors has been identified by researchers. The study highlighted its potential as a halal alternative to the two sectors seeking non-bovine and non-porcine gelatin. According to the researchers, goat skin accounted for nearly 10% of the animal's live weight and is often underutilised. The study's findings supported its valorisation into high-value gelatin, promoting circular economy practices. The research by city-based ICAR-National Meat Research Institute in collaboration with the College of Veterinary Sciences, Sri Venkateswara Veterinary University, Tirupati, compared gelatin extracted from the skins of two indigenous Indian goat breeds – Black Bengal (BBG) and Native Deccani (NDG). The study aimed to optimise the gelatin extraction process under hot air and freeze drying conditions and assess its functionality across industrial applications. The freeze dried gelatin obtained from BBG skins displayed significantly better gel strength (453g) and viscosity compared to hot air dried counterparts and NDG samples. The study also reported higher hydroxyproline content, gel clarity, and instrumental texture properties, particularly hardness, in BBG-derived gelatin. Scanning Electron Microscopy (SEM) revealed compact, interwoven protein structures in BBG gelatin with no visible voids, indicating greater uniformity and strength. Fourier Transform Infrared analysis confirmed the presence of stable triple helical structures, with distinct Amide I and II peaks in freeze dried samples. These findings suggested that gelatin from BBG skin possessed enhanced stability and functionality. Mass spectrometry of the extracted protein bands confirmed the presence of collagen type I-α1 as the predominant chain in both goat breeds, the study said. Notably, unique peptides such as collagen type XXII-α1 and α-1(III) were observed only in BBG gelatin, suggesting breed-specific functional characteristics. A species-specific peptide found in both samples provided a molecular marker for goat-based gelatin authentication, researchers said. The study was published in the latest issue of Small Ruminant Research.
Time of India
4 hours ago
- Time of India
Two new millipede species discovered in Western Ghats regions of Maharashtra and Kerala
Pune: Two new species of millipedes have been added to India's arthropod diversity after their discovery in Western Ghats regions, namely Karad in Maharashtra and in Kerala. The discovery of the two species — named Polydrepanum xiphosum and Polydrepanum spinatum — by a team of Indian scientists was published in the New Zealand-based journal Zootaxa on May 24 this year. Tired of too many ads? go ad free now The development takes the count of India's millipede species to 270, over 70% of which are endemic. Both newly found species belong to the genus Polydrepanum in the Paradoxosomatidae family. Now, the genus includes six recognised and extant species — all exclusive to the Western Ghats, which is a biodiversity hotspot. This discovery highlights the importance of conserving microhabitats within the Western Ghats, which is crucial for sustaining unique and ecologically significant species, said researchers. The study stated: "The findings highlight the region's status as a global biodiversity hotspot and the importance of its often-overlooked soil-dwelling invertebrates." Research team member Dr Aparna Sureshchandra Kalawate from the Zoological Survey of India (ZSI), Pune, told TOI, "This discovery took almost five months of rigorous work, from field collection activity in Karad and parts of Kerala to comparing them with existing taxonomic records. It became evident they didn't match any known species. We believe there may be many more such species awaiting discovery in the Ghats. " Besides Kalawate, the team comprised Dr Sudhikumar Ambalaparambil, head of the zoology department at Christ College, Irinjalakuda (Kerala), and research scholars Muhsina Musthafa (Christ College) and Pooja Misal (Shivaji University, Kolhapur). The team is currently collecting more samples and furthering their study to find different species in the Western Ghats. Tired of too many ads? go ad free now Elaborating on the importance of the tiny creatures they are studying, Kalawate shared, "Millipedes, though small and often unseen, play a crucial role in the ecosystem. As decomposers, they feed on decaying plant matter and enhance soil quality by stimulating microbial activity and releasing essential nutrients like nitrogen into the soil." Millipedes are vital components of the food chain for other invertebrates as well, said the researcher, adding, "Despite their importance, millipedes are under threat due to increasing soil pollution, land-use changes, concrete encroachment, and the overuse of fertilisers and industrial waste." The research team shared, "Millipedes are the largest macro arthropods and also known as 'indicators of environmental alteration or conditions'. They have an important role in the ecosystem, especially in the food chain, as a 'decomposer'. Although only 10% of total decomposition of plant litter within an ecosystem takes place through millipedes, their feeding enhances microbial activities, resulting in the breakdown of litter up to 90%. " Millipedes are typically found in moist environments, such as beneath decaying leaves, in the soil, and in damp areas. The scientists emphasised the need to conserve moist microhabitats in the Western Ghats — leaf litter, decaying logs, and forest soil — that are essential for the survival of these non-venomous, harmless invertebrates.
The Hindu
6 hours ago
- The Hindu
Misinformation a bigger threat than COVID-19 uptick
The reported cases of COVID-19 in India have risen from less than a few a day to a few 100 a day since mid-May 2025. Wastewater surveillance data from Indian cities have also reported an increased SARS-CoV-2 viral load. All this has resulted in heightened media and public attention because of the COVID-19 experience in 2020-21. A similar uptick in COVID-19 cases has also been reported from some other countries and regions of the world which includes Singapore, Hong Kong, Thailand and South Korea. Is there a new variant circulating? Are there reasons to worry? The current uptick in cases is being linked to the most common SARS-CoV-2 variant currently circulating, JN.1, a descendent of the Omicron variant (BA.1.529). Omicron has been the last variant of concern of SARS-CoV-2, first reported in November 2021. Since then, even though a few sub-variants or sub-lineages of Omicron have emerged, there has not been any new variant of concern, in any part of the world. The current dominant variant, JN.1 (also called Pirola) is not new and was first reported in August 2023 in Luxembourg and has been reported from India since November-December 2023. A few sub-lineages of JN.1, such as LF.7 and NB.1.8, have also been reported. But till now, there have not been any major clinical differences with the parent variant. Epidemiological facts Why this uptick? The answer lies in three epidemiological facts. First, any new virus stays for long once it enters the population, possibly forever. SARS-CoV-2 is omnipresent in India and other countries, even when no new infections are being reported. In September 2020, Moriyama M. and colleagues discussed in the scientific journal, Annual Review of Virology, that the seasonality of respiratory viruses has been recognised for thousands of years, and that the annual epidemics of the common cold and influenza disease are the most known proof. The contributing factors for seasonality are environmental parameters such as temperature and humidity, human behaviour and crowding, and changes in viral genes to alter virus stability and transmission rates. SARS-CoV-2 is a respiratory virus and is likely to have a seasonal pattern. It is just that, till now, the pattern in a rise in COVID-19 has not been established. Though some data from Singapore indicate that COVID-19 cases rise every six to nine months, the seasonality may vary from one country to another. In India, after the Omicron wave in January 2022, there were upticks in COVID-19 cases in early 2023 (due to the Omicron Sub-lineage XBB.1.16), then in December 2023 and January 2024, and then in July-August 2024. There is a fresh uptick now, from May 2025. Therefore, a seasonal pattern of COVID-19 surge, every eight to 10 months might be an emerging pattern for India. It is worthwhile to note that the number of reported cases in most seasonal surges has been relatively small and clinical disease has become mild to milder. Also read | Wastewater surveillance shows increasing COVID-19 viral load Second, SARS-CoV-2 is a type of RNA virus, which is known to have more frequent mutations and genetic changes than other types of viruses. Though the key variant continues to be JN.1, there have been some new sub-lineages, which might be behind the uptick. Third, the uptick in COVID-19 cases in India is real but also due to enhanced COVID-19 testing and surveillance, following reports of COVID-19 cases in neighbouring countries. Increased testing means more people are being tested and, thus, detection. So if the Indian population has 'hybrid immunity' from natural infection and through vaccines, and if this is not a new variant, why is there still an uptick? The answer is neither natural infection nor vaccine-induced protects from fresh infection. Immunity does protect from moderate to severe diseases and deaths. The cases or infections are a mere indicator that a person carries SARS-CoV-2 in their nose and throat. However, immune protection will ensure that people do not get sick or have severe illness. As of now, no serious cases of illness are being reported. Numbers in perspective The current uptick seems to be getting disproportionately high attention. Even with the spike, 200 to 300 new COVID-19 cases a day in India translates to one new infection for every 45 lakh to 70 lakh population. We are not hearing about hospitalisations due to COVID-19 and the deaths being attributed are one or two in a day. Let us put these numbers in perspective. The daily infections due to other illnesses are in thousands and lakhs every day. For example, every day, 8,000 new cases of tuberculosis (TB) are being reported in India. If we think in terms of deaths, every day, nearly 30,000 people in India die due to old age and other health conditions. Every day, an estimated 900 people die due to TB, a preventable and treatable health condition; another 390 due to influenza virus illness and another 310 deaths due to the relatively unheard but widely prevalent vaccine preventable Respiratory Syncytial Virus (RSV) disease. Air pollution and respiratory illnesses cause manifold illnesses and deaths. In this backdrop, COVID-19 is just another illness that is much less severe than other health issues which need greater priority. One reason why it is getting attention is because of the continuous use of old but not so relevant tracking parameters such as 'active cases', which give a falsely high number of COVID-19 cases. The approach of 'active cases' was acceptable early in the COVID-19 pandemic, when infectiousness lasted one to two weeks as the virus was novel and there was no immunity against virus in people. Therefore, after the infection, the immune system needed one to two weeks to get activated and clear the virus, prolonging the process. However, five years since then, most individuals have immunity from either vaccines or natural infections to mount a quick and effective defence and thus, be non-infectious in a day or two as well. Therefore, counting everyone who tested positive as an active case does not make sense. On vaccination There is no need for an additional COVID-19 vaccine dose. In the first three years of COVID-19 (2020-22), the Indian population (all age groups) had been exposed to various variants of SARS-CoV-2 including Omicron. Alongside this, nearly all adults received two or more shots of COVID-19 vaccines. Therefore, the population in our country has 'hybrid immunity' against SARS-CoV-2. Most people were exposed to the Omicron variant in December 2022 and January 2023. And JN.1, the circulating dominant variant, is from the Omicron family. It is likely that antibody levels would have gone down and there is waning immunity. Thus some immune escape to new sub-variants is possible. However, the human immune system has specialised cells called 'memory cells' which are largely undetectable but are programmed to respond to future infections and are likely to protect against future severe illness. There is no new variant of concern to believe immune escape, as of now. Scientifically, there is no need and thus no recommendation for additional shots of COVID-19 vaccine for the Indian population. COVID-19 is not a concern and the prevention and the treatment of any pre-existing health condition is much more effective than 'additional COVID-19' shots. Thus, those with high risk should get vaccinated with flu and other age-appropriate recommended vaccines to prevent any comorbidity. The current uptick in COVID-19 in Asia and India seems to follow an emerging seasonal pattern of SARS-CoV-2. There does not seem to be any reason for worry. All that is needed is for the government to keep a watch and monitor the trends. The Infodemic and misinformation could be a bigger threat than a minor uptick in COVID-19 cases. For India, for both government and citizens, there needs to be a balanced approach — neither underestimating the threat nor spreading panic. One important tool in this is not to spread unverified messages and rumours. There is a need for a rational, epidemiological and balanced approach in reporting and responding to the current and future seasonal spikes in COVID-19. If we continue to treat every spike as an impending 'wave' and as a 'false alarm', it will strain the health system and workforce, resulting in response fatigue and undermining credibility. Responses to COVID-19 surges must be rational, proportionate and reflective of epidemiological reality. Current evidence is that from now, COVID-19 could be treated like any other mild respiratory illness. Dr. Chandrakant Lahariya is a practising physician and a leading epidemiologist and global health expert, who has nearly 17 years of professional work experience with the World Health Organization and other UN agencies
